2 completed, 1 terminated, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
Follow ISIS 113715: new trials by email Literature Review of ISIS 113715 trials Research Report on ISIS 113715
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea ISIS 113715 - Type 2 Diabetes Mellitus | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 88 | 2007-02-01 | 2009-08-28 |
| Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea ISIS 113715 - Type 2 Diabetes Mellitus | Phase 2 | Withdrawn | Ionis Pharmaceuticals, Inc. | 2006-05-01 | 2022-12-05 | |
| Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics ISIS 113715 - Type 2 Diabetes Mellitus | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 2 | 2005-11-01 | 2022-12-05 |
| Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment ISIS 113715 - Type 2 Diabetes Mellitus | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 96 | 2003-02-01 | 2008-02-06 |
Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus (1)
Ionis Pharmaceuticals, Inc. (4)
Poland (2) · Russia (2) · Israel (1) · Romania (1) · United States (1)
Mark K Wedel, MD, JD, FACP (2)